BACKGROUND: Current estimates of the costs of cancer care in the United States are based on data from 2003 and earlier. However, incidence, survival, and practice patterns have been changing for the majority of cancers. METHODS: Cancer prevalence was estimated and projected by phase of care (initial year following diagnosis, continuing, and last year of life) and tumor site for 13 cancers in men and 16 cancers in women through 2020. Cancer prevalence was calculated from cancer incidence and survival models estimated from Surveillance, Epidemiology, and End Results (SEER) Program data. Annualized net costs were estimated from recent SEER-Medicare linkage data, which included claims through 2006 among beneficiaries aged 65 years and older with a cancer diagnosis. Control subjects without cancer were identified from a 5% random sample of all Medicare beneficiaries residing in the SEER areas to adjust for expenditures not related to cancer. All cost estimates were adjusted to 2010 dollars. Different scenarios for assumptions about future trends in incidence, survival, and cost were assessed with sensitivity analysis. RESULTS: Assuming constant incidence, survival, and cost, we projected 13.8 and 18.1 million cancer survivors in 2010 and 2020, respectively, with associated costs of cancer care of 124.57 and 157.77 billion 2010 US dollars. This 27% increase in medical costs reflects US population changes only. The largest increases were in the continuing phase of care for prostate cancer (42%) and female breast cancer (32%). Projections of current trends in incidence (declining) and survival (increasing) had small effects on 2020 estimates. However, if costs of care increase annually by 2% in the initial and last year of life phases of care, the total cost in 2020 is projected to be $173 billion, which represents a 39% increase from 2010. CONCLUSIONS: The national cost of cancer care is substantial and expected to increase because of population changes alone. Our findings have implications for policy makers in planning and allocation of resources.
BACKGROUND: Current estimates of the costs of cancer care in the United States are based on data from 2003 and earlier. However, incidence, survival, and practice patterns have been changing for the majority of cancers. METHODS:Cancer prevalence was estimated and projected by phase of care (initial year following diagnosis, continuing, and last year of life) and tumor site for 13 cancers in men and 16 cancers in women through 2020. Cancer prevalence was calculated from cancer incidence and survival models estimated from Surveillance, Epidemiology, and End Results (SEER) Program data. Annualized net costs were estimated from recent SEER-Medicare linkage data, which included claims through 2006 among beneficiaries aged 65 years and older with a cancer diagnosis. Control subjects without cancer were identified from a 5% random sample of all Medicare beneficiaries residing in the SEER areas to adjust for expenditures not related to cancer. All cost estimates were adjusted to 2010 dollars. Different scenarios for assumptions about future trends in incidence, survival, and cost were assessed with sensitivity analysis. RESULTS: Assuming constant incidence, survival, and cost, we projected 13.8 and 18.1 million cancer survivors in 2010 and 2020, respectively, with associated costs of cancer care of 124.57 and 157.77 billion 2010 US dollars. This 27% increase in medical costs reflects US population changes only. The largest increases were in the continuing phase of care for prostate cancer (42%) and female breast cancer (32%). Projections of current trends in incidence (declining) and survival (increasing) had small effects on 2020 estimates. However, if costs of care increase annually by 2% in the initial and last year of life phases of care, the total cost in 2020 is projected to be $173 billion, which represents a 39% increase from 2010. CONCLUSIONS: The national cost of cancer care is substantial and expected to increase because of population changes alone. Our findings have implications for policy makers in planning and allocation of resources.
Authors: T J Smith; L Penberthy; C E Desch; M Whittemore; C Newschaffer; B E Hillner; D McClish; S M Retchin Journal: Lung Cancer Date: 1995-12 Impact factor: 5.705
Authors: Matthew Kerrigan; Nadia Howlader; Margaret T Mandelson; Robert Harrison; Edward C Mansley; Scott D Ramsey Journal: Med Care Date: 2005-10 Impact factor: 2.983
Authors: S H Taplin; W Barlow; N Urban; M T Mandelson; D J Timlin; L Ichikawa; P Nefcy Journal: J Natl Cancer Inst Date: 1995-03-15 Impact factor: 13.506
Authors: Darla E Kendzor; Michael S Businelle; Insiya B Poonawalla; Erica L Cuate; Anshula Kesh; Debra M Rios; Ping Ma; David S Balis Journal: Am J Public Health Date: 2014-11-13 Impact factor: 9.308
Authors: Shivani Pahwa; Nicholas K Schiltz; Lee E Ponsky; Ziang Lu; Mark A Griswold; Vikas Gulani Journal: Radiology Date: 2017-05-17 Impact factor: 11.105
Authors: Michaela A Dinan; Yanhong Li; Yinghong Zhang; Suzanne B Stewart; Lesley H Curtis; Daniel J George; Shelby D Reed Journal: Clin Genitourin Cancer Date: 2015-08-06 Impact factor: 2.872
Authors: Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman Journal: Lancet Date: 2018-01-31 Impact factor: 79.321
Authors: Fevzi F Yalniz; Mohammad H Murad; Stephanie J Lee; Steven Z Pavletic; Nandita Khera; Nilay D Shah; Shahrukh K Hashmi Journal: Biol Blood Marrow Transplant Date: 2018-03-14 Impact factor: 5.742
Authors: May Darwish-Yassine; Manijeh Berenji; Diane Wing; Glenn Copeland; Raymond Y Demers; Carol Garlinghouse; Angela Fagerlin; Gail E Newth; Laurel Northouse; Margaret Holmes-Rovner; David Rovner; Jerry Sims; John T Wei Journal: J Cancer Surviv Date: 2013-11-10 Impact factor: 4.442